Q4 2025 Amphastar Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Amphastar Pharmaceuticals Inc (AMPH) achieved FDA approval for Ipratropium Bromide HFA Inhalation Aerosol, which is eligible for 180 days of generic drug exclusivity.
- The company reported strong growth in BAQSIMI sales, with a 12% increase year-over-year, contributing significantly to overall revenue.
- Amphastar expanded its proprietary pipeline with the addition of novel peptides in oncology and ophthalmology, and a synthetic corticotropin program in immunology.
- The company maintained resilient commercial momentum with products like Primatene Mist, which saw a 7% increase in sales.
- Amphastar's US manufacturing expansion in Rancho Cucamonga is set to quadruple production capacity, enhancing scalability and supply reliability.
- Overall sales for the fourth quarter of 2025 decreased by 2% compared to the previous year, reflecting challenges in legacy products.
- Glucagon sales declined by 45% due to increased competition and a market shift towards ready-to-use products.
- Epinephrine sales fell by 9% due to heightened competition in the multi-dose vial market.
- Gross margins are expected to be lower in 2026 due to pricing pressures on high-margin products like glucagon and epinephrine.
- General and administrative expenses increased by 27% due to higher legal costs and the implementation of a new ERP system.
Greetings and welcome to the Amphastar Pharmaceuticals fourth quarter earnings call. (Operator instructions)These statements are based solely on information that is now available to us. We encourage you to review the session entitled forward-looking Statements in the Press Release issued today and the Presentation on the company's website. Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures.
Important information on our use of these measures and reconciliations to US GAAP may be found in our earnings release. Please note this conference is being recorded. Our speakers today are Mr. Bill Peters, CFO, Mr. Dan Disner, senior Vice President of Corporate communications, and Mr. Tony Marrs, executive Vice President of Regulatory Affairs and Clinical Operations. I will now turn the conference over to your host, Mr. Dan Dischner, Senior Vice President of Corporate communications. Dan, you may begin.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
